GlassScriptPhysician profile
David Joseph Young
NPI 1194817627
$772.52
in general payments reported to CMS, 2019-2025
12 companies · $34.17 in 2025
The $34.17 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $13.77 · 2021: $33.30 · 2023: $43.82 · 2024: $160 · 2025: $34.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $180.02 | 2019 | |
| Sunovion Pharmaceuticals INC. | $115.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.29 | 2019-2023 | Ofev |
| Grifols USA, LLC | $98.57 | 2024 | Prolastin-C Liquid |
| Alexion Pharmaceuticals, INC. | $82.62 | 2019-2024 | Ultomiris |
| Actelion Pharmaceuticals US, INC. | $67.66 | 2019-2024 | Opsumit |
| Glaxosmithkline, LLC. | $33.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2024 | Glassia |
| Paratek Pharmaceuticals, INC. | $19.42 | 2025 | Nuzyra |
| Allergan, INC. | $18.40 | 2019 | |
| Lilly USA, LLC | $14.75 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.